CymaBay Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de CymaBay Therapeutics es Sujal Shah , nombrado en Mar 2017, tiene una permanencia de 6.75 años. compensación anual total es $2.56M, compuesta por 23% salario y 77% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.35% de las acciones de la empresa, por valor de $13.20M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 7 años, respectivamente.
Información clave
Sujal Shah
Chief Executive Officer (CEO)
US$2.6m
Compensación total
| Porcentaje del salario del CEO | 23.0% |
| Permanencia del CEO | 7yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 7yrs |
Actualizaciones recientes de la dirección
Recent updates
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%
Feb 15
Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher
Dec 22CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
Dec 28CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01
Aug 11Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Jul 13CymaBay: Long-Term Potential Based On Prior PBC Trial Results
Jun 27Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?
Mar 17Why I've Taken A 'Starter' Position In CymaBay Therapeutics
Jan 20Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Dec 03We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
May 15We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely
Jan 29
CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow
Nov 17CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion
Nov 08CymaBay Therapeutics EPS in-line
Nov 05Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$90m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$107m |
| Dec 31 2022 | US$3m | US$590k | -US$106m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$104m |
| Mar 31 2022 | n/a | n/a | -US$100m |
| Dec 31 2021 | US$2m | US$550k | -US$90m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$55m |
| Dec 31 2020 | US$3m | US$510k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$65m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$93m |
| Dec 31 2019 | US$3m | US$510k | -US$103m |
| Sep 30 2019 | n/a | n/a | -US$93m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$2m | US$452k | -US$73m |
| Sep 30 2018 | n/a | n/a | -US$58m |
| Jun 30 2018 | n/a | n/a | -US$48m |
| Mar 31 2018 | n/a | n/a | -US$39m |
| Dec 31 2017 | US$5m | US$393k | -US$28m |
Compensación vs. Mercado: La compensación total de Sujal($USD2.56M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.56M).
Compensación vs. Ingresos: La compensación de Sujal ha aumentado mientras la empresa no es rentable.
CEO
Sujal Shah (50 yo)
7yrs
Permanencia
US$2,561,783
Compensación
Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7yrs | US$2.56m | 0.35% $ 13.2m | |
| President of Research & Development and Chief Scientific Officer | 11.2yrs | US$1.23m | 0.041% $ 1.5m | |
| General Counsel | 3.4yrs | US$1.10m | 0.061% $ 2.3m | |
| CFO, Principal Accounting & Financial Officer | less than a year | sin datos | 0.018% $ 653.5k | |
| Senior Vice President of Human Resources | 3.7yrs | sin datos | sin datos | |
| Senior Vice President of Business Development | 7.2yrs | sin datos | sin datos | |
| Senior Vice President of Manufacturing & Nonclinical Development | 8.9yrs | sin datos | sin datos | |
| Chief Regulatory & Quality Assurance Officer | 3.4yrs | US$1.24m | 0.018% $ 681.8k | |
| Senior Vice President of Portfolio & Product Leadership | 3.3yrs | sin datos | sin datos | |
| Head of Commercial | less than a year | sin datos | sin datos |
3.5yrs
Permanencia media
60.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CBAY se considera experimentado (3.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.8yrs | US$2.56m | 0.35% $ 13.2m | |
| Independent Director | 2.9yrs | US$207.94k | 0% $ 0 | |
| Member of Clinical Advisory Board and Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.3yrs | US$215.44k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman | 9yrs | US$245.44k | 0.026% $ 974.1k |
7.0yrs
Permanencia media
69yo
Promedio de edad
Junta con experiencia: La junta directiva de CBAY se considera experimentada (7 años de antigüedad promedio).